The Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME.
Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY.
Blood Adv. 2022 Jun 28;6(12):3666-3677. doi: 10.1182/bloodadvances.2022006968.
In adult acute myeloid leukemia (AML), the acquisition of driver somatic mutations may be preceded by a benign state termed clonal hematopoiesis (CH). To develop therapeutic strategies to prevent leukemia development from CH, it is important to understand the mechanisms by which CH-driving and AML-driving mutations cooperate. Here, we use mice with inducible mutant alleles common in human CH (DNMT3AR882; mouse Dnmt3aR878H) and AML (NPM1c; mouse Npm1cA). We find that Dnmt3aR878H/+ hematopoietic stem cells (HSCs), but not multipotent progenitor cell (MPP) subsets, have reduced cytokine expression and proinflammatory transcriptional signatures and a functional competitive advantage over their wild-type counterparts. Dnmt3aR878H/+ HSCs are the most potent cell type transformed by Npm1cA, generating myeloid malignancies in which few additional cooperating somatic mutation events were detected. At a molecular level, Npm1cA, in cooperation with Dnmt3aR878H, acutely increased the accessibility of a distinct set of promoters in HSCs compared with MPP cells. These promoters were enriched for cell cycling, PI3K/AKT/mTOR signaling, stem cell signatures, and targets of transcription factors, including NFAT and the chromatin binding factor HMGB1, which have been implicated in human AML. These results demonstrate cooperativity between preexisting Dnmt3aR878H and Npm1cA at the chromatin level, where specific loci altered in accessibility by Npm1cA are dependent on cell context as well as Dnmt3a mutation status. These findings have implications for biological understanding and therapeutic intervention in the transformation from CH to AML.
在成人急性髓系白血病 (AML) 中,获得驱动体细胞突变之前,可能存在一种良性状态,称为克隆性造血 (CH)。为了开发预防 CH 驱动白血病发展的治疗策略,了解 CH 驱动和 AML 驱动突变相互作用的机制非常重要。在这里,我们使用了具有人类 CH(DNMT3AR882;小鼠 Dnmt3aR878H)和 AML(NPM1c;小鼠 Npm1cA)中常见的诱导突变等位基因的小鼠。我们发现,Dnmt3aR878H/+造血干细胞 (HSCs),而不是多能祖细胞 (MPP) 亚群,其细胞因子表达和促炎转录特征减少,并且具有相对于其野生型细胞的功能竞争优势。Dnmt3aR878H/+ HSCs 是最有能力被 Npm1cA 转化的细胞类型,产生了很少检测到其他协同体细胞突变事件的髓系恶性肿瘤。在分子水平上,Npm1cA 与 Dnmt3aR878H 合作,与 MPP 细胞相比,急性增加了 HSCs 中一组独特启动子的可及性。这些启动子富含细胞周期、PI3K/AKT/mTOR 信号通路、干细胞特征以及转录因子 NFAT 和染色质结合因子 HMGB1 的靶标,这些因子已被牵连到人类 AML 中。这些结果表明,在染色质水平上,预先存在的 Dnmt3aR878H 和 Npm1cA 之间存在协同作用,Npm1cA 改变可及性的特定基因座既依赖于细胞环境,也依赖于 Dnmt3a 突变状态。这些发现对从 CH 到 AML 的转化的生物学理解和治疗干预具有重要意义。